Inotiv Executive and Leadership Team

Robert Leasure, the Chief Executive Officer & President at Inotiv, directs the overarching corporate strategy and long-term vision for the organization. Overseeing the integration of scientific capabilities across the drug discovery continuum, the Chief Executive Officer & President ensures that all business units maintain alignment with the company's commitment to quality data delivery. This leadership role involves managing relationships with the Board and driving expansion across North American markets to solidify the company's position as a premier CRO. By prioritizing operational efficiency and regulatory compliance, Robert Leasure fosters a culture of attentive, decisive service for every client program. The Chief Executive Officer & President maintains a focus on scaling the business to meet the evolving needs of the pharmaceutical industry, ensuring that Inotiv remains a trusted partner for complex research projects from discovery through the investigational new drug phase.

Greg Beattie, the Chief Operating Officer at Inotiv, manages the daily execution of scientific services and operational workflows across the organization. Overseeing the internal processes that support the discovery and development continuum, the Chief Operating Officer ensures that laboratory operations meet rigorous quality standards and timelines. This role involves coordinating with department heads to optimize resource allocation and improve the delivery of research data to global clients. By streamlining cross-functional collaboration, Greg Beattie drives the operational excellence required to maintain the company's impeccable regulatory history. The Chief Operating Officer monitors performance metrics to identify opportunities for process improvement, ensuring that every project receives the necessary attention and scientific rigor. Through the implementation of scalable operational frameworks, Beattie supports the company's mission to provide a superlative experience for partners navigating the complex path from initial discovery to clinical trials.

Lizanne Muller, the Group President, RMS at Inotiv, oversees the supply and management of critical research models, including rodents, rabbits, and nonhuman primates. Directing the operations of the Research Model Services division, the Group President, RMS ensures that these essential assets meet the highest standards of quality and regulatory compliance for global research projects. This role involves managing the logistics and welfare protocols that underpin the company's reputation for excellence in the scientific community. By coordinating with internal research teams, Lizanne Muller ensures that the supply chain remains robust and responsive to the needs of clients at every stage of the discovery continuum. The Group President, RMS drives initiatives to expand the reach of these services, supporting the company's mission to provide a superlative experience for researchers. Through strategic oversight of model production and distribution, Muller maintains the integrity of the research pipeline for partners worldwide.

Alison Bendele, the Founder and President of Bolder BioPATH at Inotiv, leads the specialized bio-pathology and pharmacology research services that define the company's scientific depth. Overseeing the execution of complex studies, the Founder and President of Bolder BioPATH ensures that every project receives the rigorous analysis required for successful drug development. This role involves guiding the scientific team in delivering high-quality data that supports clients from the beginning of discovery through the investigational new drug phase. By maintaining a focus on specialized research methodologies, Alison Bendele contributes to the company's reputation for world-class scientific expertise. The Founder and President of Bolder BioPATH collaborates with other executive leaders to integrate these specialized services into the broader CRO offering, ensuring a seamless experience for partners. Through the application of deep technical knowledge, Bendele drives the innovation and precision that characterize the company's approach to complex preclinical research.

Becky Dolliver, the Chief Information Officer at Inotiv, architects the digital infrastructure and data management systems essential for high-stakes scientific research. Overseeing the security and integrity of sensitive client data, the Chief Information Officer ensures that all technological platforms support the seamless transition of information from discovery through the investigational new drug phase. This role involves integrating advanced analytics tools to enhance the quality and speed of data delivery for research projects. By modernizing the company's IT landscape, Becky Dolliver enables the scientific team to focus on core research objectives without technical friction. The Chief Information Officer collaborates with executive leadership to align digital initiatives with the company's broader growth strategy, ensuring that technological capabilities scale alongside the business. Through the deployment of robust cybersecurity measures, Dolliver protects the intellectual property of clients while maintaining the high standards of service expected from a world-class CRO.

Jeff Krupp, the Chief Human Resources Officer at Inotiv, directs the talent acquisition and organizational development strategies necessary to sustain a world-class team of scientists. Overseeing the recruitment of specialized personnel, the Chief Human Resources Officer ensures that the company maintains the deep expertise required for complex drug discovery and research model services. This role involves fostering a high-performance culture that prioritizes attentive, decisive service for every client program. By implementing comprehensive training and retention programs, Jeff Krupp supports the professional growth of the workforce, which directly impacts the quality of data delivered to partners. The Chief Human Resources Officer collaborates with the executive team to align human capital strategies with the company's operational goals and market expansion efforts. Through the management of organizational structure and employee engagement, Krupp ensures that the company remains a preferred destination for top-tier scientific talent in the competitive CRO landscape.